Table 2.
Renal risk drugs (RRD) and renal drug-related problems (rDRP) in patients with eGFRnon-indexed 15–59 ml/min and ≥ 1 drug (n = 190). Data are quoted as the median (interquartile range) or n (%)
| eGFR categories | |||||
|---|---|---|---|---|---|
| eGFRnon-indexed (ml/min) | Overall 15–59 | 15–29 | 30–44 | 45–59 | |
| No. of patients | n | 190 | 39 | 56 | 95 |
| Drugs at admission | n | 1209 | 278 | 361 | 570 |
| median (range) | 6 (1–18) | 6 (1–18) | 6 (1–17) | 5 (1–14) | |
| Renal Risk Drugs (RRD) | n (%) | 660 (54.7) | 160 (57.5) | 187 (51.8) | 313 (54.9) |
| No. of RRD per patient | median (range) | 3 (0–11) | 4 (0–11) | 3 (0–10) | 3 (0–9) |
| RRD with rDRP | n (%) | 264* (21.8**) | 107* (38.5**) | 85* (23.5**) | 72* (12.6**) |
| Patients with rDRP | n (%) | 115 (60.5) | 31 (79.5) | 35 (62.5) | 49 (51.6) |
| No. of rDRP per patient | median (range) | 2 (0–10) | 2 (0–10) | 2 (0–7) | 1 (0–4) |
| No. of rDRP | n | 260 | 105 | 85 | 70 |
| Potentiala | n (%) | 108 (41.5) | 14 (13.3) | 61 (71.8) | 33 (47.1) |
| with only monitoringb | n (%) | 10 (9.3#) | 0 (0.0) | 6 (10.0#) | 4 (12.1#) |
| Manifestc | n (%) | 152 (58.5) | 91 (86.7) | 24 (28.2) | 37 (52.9) |
| with only monitoringb | n (%) | 57 (37.2#) | 26 (28.6#) | 14 (56.0#) | 17 (45.9#) |
*Drugs were counted separately, when there was a drug interaction potentially decreasing renal function (two or three drugs per interaction)
**Percentage value refers to drugs at admission
#Percentage value refers to potential or manifest rDRP
a: eGFR must be monitored, if it decreases, action must be taken
b: Monitoring as only intervention: Serum blood value (e.g. electrolytes) or adverse drug reaction must be monitored
c: rDRP is currently present with the current eGFR